{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:49:51Z","timestamp":1781570991912,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004215","name":"Pantarhei Bioscience BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004215","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.euros.2021.04.005","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T17:00:19Z","timestamp":1620320419000},"page":"52-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-9400","authenticated-orcid":false,"given":"Herjan J.T.","family":"Coelingh Bennink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.M.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton A.","family":"Roeleveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjard D.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm H.E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacov","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonnie","family":"van Osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Krijgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew V.","family":"Schally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M.J.","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2021.04.005_bib0005","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.euros.2021.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jama.1996.03530390019013","article-title":"Estrogen therapy for prostate carcinoma","volume":"275","author":"Presti","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2021.04.005_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/21681805.2013.861508","article-title":"Diethylstilboestrol for the treatment of prostate cancer: past, present and future","volume":"48","author":"Turo","year":"2014","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euros.2021.04.005_bib0020","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0006-291X(71)80019-0","article-title":"Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence","volume":"43","author":"Matsuo","year":"1971","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.euros.2021.04.005_bib0025","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1210\/jc.2018-00147","article-title":"A dose-escalating study with the fetal estrogen estetrol in healthy men","volume":"103","author":"Coelingh Bennink","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euros.2021.04.005_bib0030","first-page":"10167","article-title":"The role of FSH and LH in prostate cancer and cardiometabolic comorbidities","volume":"27","author":"Crawford","year":"2020","journal-title":"Can J Urol"},{"key":"10.1016\/j.euros.2021.04.005_bib0035","first-page":"207","article-title":"Metabolism of 17-beta-oestradiol-4-14-C in early infancy","volume":"49","author":"Hagen","year":"1965","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"Suppl 1","key":"10.1016\/j.euros.2021.04.005_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13697130802073425","article-title":"Estetrol review: profile and potential clinical applications","volume":"11","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"issue":"Suppl 1","key":"10.1016\/j.euros.2021.04.005_bib0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13697130701798692","article-title":"Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model","volume":"11","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.euros.2021.04.005_bib0050","first-page":"463","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.euros.2021.04.005_bib0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.euros.2021.04.005_bib0060","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.euros.2021.04.005_bib0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/GME.0000000000000823","article-title":"Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study","volume":"24","author":"Coelingh Bennink","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.euros.2021.04.005_bib0070","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.15252\/emmm.201404112","article-title":"The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation","volume":"6","author":"Abot","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.euros.2021.04.005_bib0075","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1152\/physrev.00024.2016","article-title":"Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications","volume":"97","author":"Arnal","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.euros.2021.04.005_bib0080","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.euros.2021.04.005_bib0085","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2021.04.005_bib0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","article-title":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy","volume":"11","author":"Nishiyama","year":"2004","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2021.04.005_bib0095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2021.04.005_bib0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2021.04.005_bib0105","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"2004","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euros.2021.04.005_bib0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2021.04.005_bib0115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2021.04.005_bib0120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/21681805.2018.1522372","article-title":"FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist","volume":"52","author":"Crawford","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euros.2021.04.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.12.011","article-title":"Cell-based evidence regarding the role of FSH in prostate cancer","volume":"37","author":"Dizeyi","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2021.04.005_bib0130","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.urology.2014.02.001","article-title":"Maximal testosterone suppression in prostate cancer\u2014free vs total testosterone","volume":"83","author":"Rove","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.euros.2021.04.005_bib0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/pros.23256","article-title":"Free testosterone during androgen deprivation therapy predicts castration-resistant progression better than total testosterone","volume":"77","author":"Regis","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2021.04.005_bib0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrurol.2010.231","article-title":"Blockade of testicular and adrenal androgens in prostate cancer treatment","volume":"8","author":"Labrie","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2021.04.005_bib0145","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","article-title":"The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer","volume":"10","author":"Nishiyama","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2021.04.005_bib0150","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.ijrobp.2012.08.036","article-title":"PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era","volume":"85","author":"McGuire","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euros.2021.04.005_bib0155","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2021.04.005_bib0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijrobp.2009.01.030","article-title":"Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial","volume":"76","author":"Alexander","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168321000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168321000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:05:37Z","timestamp":1762977937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168321000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"alternative-id":["S2666168321000793"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2021.04.005","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2021.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}